CN1297548C - 环状半缩醛衍生物及其应用 - Google Patents

环状半缩醛衍生物及其应用 Download PDF

Info

Publication number
CN1297548C
CN1297548C CNB038061104A CN03806110A CN1297548C CN 1297548 C CN1297548 C CN 1297548C CN B038061104 A CNB038061104 A CN B038061104A CN 03806110 A CN03806110 A CN 03806110A CN 1297548 C CN1297548 C CN 1297548C
Authority
CN
China
Prior art keywords
compound
amino
methyl
straight
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038061104A
Other languages
English (en)
Chinese (zh)
Other versions
CN1642933A (zh
Inventor
中村雅之
井上淳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senju Pharmaceutical Co Ltd
Original Assignee
Senju Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharmaceutical Co Ltd filed Critical Senju Pharmaceutical Co Ltd
Publication of CN1642933A publication Critical patent/CN1642933A/zh
Application granted granted Critical
Publication of CN1297548C publication Critical patent/CN1297548C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/22—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Liquid Crystal Substances (AREA)
CNB038061104A 2002-03-15 2003-03-14 环状半缩醛衍生物及其应用 Expired - Fee Related CN1297548C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002072762 2002-03-15
JP072762/2002 2002-03-15

Publications (2)

Publication Number Publication Date
CN1642933A CN1642933A (zh) 2005-07-20
CN1297548C true CN1297548C (zh) 2007-01-31

Family

ID=28035193

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038061104A Expired - Fee Related CN1297548C (zh) 2002-03-15 2003-03-14 环状半缩醛衍生物及其应用

Country Status (10)

Country Link
US (1) US7202274B2 (enExample)
EP (1) EP1489076B1 (enExample)
JP (2) JPWO2003078415A1 (enExample)
KR (1) KR101016593B1 (enExample)
CN (1) CN1297548C (enExample)
AT (1) ATE404548T1 (enExample)
AU (1) AU2003220928A1 (enExample)
DE (1) DE60322856D1 (enExample)
ES (1) ES2307915T3 (enExample)
WO (1) WO2003078415A1 (enExample)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1106001A (zh) * 1993-09-03 1995-08-02 武田药品工业株式会社 乳醇衍生物及其制备方法和用途
WO1996025408A1 (en) * 1995-02-14 1996-08-22 Mitsubishi Chemical Corporation Oxygen-containing heterocyclic derivatives
WO1998004539A1 (en) * 1996-07-29 1998-02-05 Mitsubishi Chemical Corporation Oxygenic heterocyclic derivatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06504547A (ja) * 1990-12-28 1994-05-26 ジョージア・テック・リサーチ・コーポレーション ペプチドケトアミド、ケト酸およびケトエステル
HUT71250A (en) 1992-05-20 1995-11-28 Senju Pharma Co Remedy for cataract and production thereof
JP2825172B2 (ja) 1992-07-10 1998-11-18 東京エレクトロン株式会社 減圧処理装置および減圧処理方法
JPH08104685A (ja) * 1993-09-03 1996-04-23 Takeda Chem Ind Ltd ラクトール誘導体、その製造法および用途
US5498616A (en) * 1994-11-04 1996-03-12 Cephalon, Inc. Cysteine protease and serine protease inhibitors
JPH09169752A (ja) 1995-02-14 1997-06-30 Mitsubishi Chem Corp 含酸素複素環誘導体
DE69625575T2 (de) * 1995-10-25 2003-09-25 Senju Pharmaceutical Co., Ltd. Angiogense-Inhibitor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1106001A (zh) * 1993-09-03 1995-08-02 武田药品工业株式会社 乳醇衍生物及其制备方法和用途
WO1996025408A1 (en) * 1995-02-14 1996-08-22 Mitsubishi Chemical Corporation Oxygen-containing heterocyclic derivatives
WO1998004539A1 (en) * 1996-07-29 1998-02-05 Mitsubishi Chemical Corporation Oxygenic heterocyclic derivatives

Also Published As

Publication number Publication date
CN1642933A (zh) 2005-07-20
ES2307915T3 (es) 2008-12-01
EP1489076B1 (en) 2008-08-13
ATE404548T1 (de) 2008-08-15
JPWO2003078415A1 (ja) 2005-07-14
EP1489076A4 (en) 2005-12-21
KR20050006130A (ko) 2005-01-15
US20050119499A1 (en) 2005-06-02
US7202274B2 (en) 2007-04-10
EP1489076A1 (en) 2004-12-22
JP2010189424A (ja) 2010-09-02
KR101016593B1 (ko) 2011-02-22
WO2003078415A1 (en) 2003-09-25
DE60322856D1 (enExample) 2008-09-25
AU2003220928A1 (en) 2003-09-29

Similar Documents

Publication Publication Date Title
CN1210268C (zh) ((环)烷基取代的)－γ－氨基丁酸衍生物(=GABA类似物),其制备和在治疗神经病中的用途
CN1131855C (zh) 1－取代－1－氨基甲基－环烷衍生物(=加巴喷丁类似物)、其制备及其在治疗神经病方面的用途
CN1281606C (zh) 含氮杂环化合物
CN1065536C (zh) 2－甲基－噻吩并苯并二氮杂䓬的结晶形式及制备方法
CN1028992C (zh) 1，4，-苯并硫杂吖庚因衍生物的制备方法
CN85107020A (zh) 烷基亚磺酰胺基苯基烷基胺的制备方法
CN1140165A (zh) 芳基磺酰基异羟肟酸衍生物
JP2008163035A (ja) ノイラミニダーゼ阻害剤として有用な置換シクロペンタン及びシクロペンテン化合物
RS56424B1 (sr) Piridin-2-amidi korisni kao cb2-agonisti
CN1438991A (zh) 作为中性内肽酶的抑制剂的环戊基－取代的戊二酰胺衍生物
CN1304447A (zh) 通过抑制木瓜蛋白酶超家族的半胱氨酸蛋白酶治疗寄生虫病
EP2318414A2 (fr) Derives imidazo [1,2-a] pyrimidine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et utilisation comme inhibiteurs de met
WO2022072975A1 (en) Compositions and methods of treatment for sars-cov-2 through papain protease inhibition
CN1420878A (zh) 具有释放生长激素特性的化合物
US20240383920A1 (en) Synthesis of ras inhibitors
CN1031619C (zh) 噁唑烷酮衍生物用于制备药物
CN1147297C (zh) 新型七叶亭衍生物及医药组合物
CN1756757A (zh) 吡咯并咪唑衍生物、其制备、包含它们的药物组合物及其作为向精神剂的应用
JP2000509717A (ja) オキシランメタンアミン誘導体の調製方法
CN1297548C (zh) 环状半缩醛衍生物及其应用
CN1079789C (zh) 新的羟肟酸衍生物,包含它们的药物组合物及其制法
CN1097745A (zh) 取代的哌嗪
TW202515556A (zh) Ｓｌｃ６ａ１９功能之含萘基哌啶抑制劑
CN1267407C (zh) 兴奋性氨基酸前体药物
CN1274712C (zh) 肽衍生物及其药学上可接受的盐、其制造法及用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070131

Termination date: 20130314